The patients had all had prior surgery and were randomly ass mai mult [Articles] Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with aberrations: a phase 2, single-arm trial 31 Decembrie The activity and safety profile of single-agent ibrutinib in CLL with TP53 aberrations is encouraging and supports its consideration as a novel treatment option for patients with this high-risk disease in both first-line and second-line settings.
III colon adenocarcinoma.
Implementation of CME surgery might improve outcomes for patients with colon cancer. Further stud mai mult [Comment] Sunitinib in thymic carcinoma: enigmas still unresolved 13 Ianuarie Beyond surgery, the optimum treatment for thymic epithelial tumours is unresolved owing to their rarity, histological heterogeneity, and unknown molecular pathogenesis.
Further studies are needed to identify potential biomarkers of activity. Cetuximab is a lid margin papilloma excision mouse IgG1 monoclonal anti-EGFR antibody, and panitumumab is a fu mai mult [Articles] Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck CONCERT-1 : a randomised, controlled, open-label phase 2 trial 15 Ianuarie In patients with locally advanced squamous-cell carcinoma of the head and neck, the addition of panitumumab to standard fractionation radiotherapy and cisplatin did not confer any benefit, and the role of EGFR inhibition in these patients needs to be reassessed.
IVb squamous-cell carcinoma of the head and neck, and the role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and neck needs to be reassessed. Patients were randomly assigned to receive high-dose 74 Gy in 37 fractions or standard dose 60 Gy in 30 fractions radiotherapy mai mult [Articles] Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer Virus del papiloma humano en ingles : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study 16 Ianuarie In this randomised phase 3 trial with a median follow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant.
These results further support the favourable safety profile mai mult [News] Commercial lid margin papilloma excision banned in Australia 16 Ianuarie Commercial solariums have been banned across most of Australia from Jan 1,after a long-running campaign by cancer bodies and patients with melanoma.
The single group study administered the therapy prospectively to patients with small, node-negative, HER2-positive tumours. Treatm mai mult [Articles] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer RTOG : a randomised, two-by-two factorial phase 3 study 16 Ianuarie 74 Gy radiation given in 2 Gy fractions with concurrent chemotherapy was not better than 60 Gy plus lid margin papilloma excision chemotherapy for patients with stage III non-small-cell lung cancer, and might be potentially harmful.
The risk of development of gastric cancer is high in families affected b-y these syndromes, but o mai mult.